Additionally, the combination of HAIC, TKI, and PD-1 inhibitors (one type of immune checkpoint inhibitors) (triple therapy) has shown promising efficacy and safety in several phase II trials, especially in patients with high tumor burden10,11. The gene discussed is PDCD1; the disease is neoplasm.